dobutamine has been researched along with 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2h)-pyridazinone in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erhardt, PW | 1 |
| Keren, G; LeJemtel, TH; Reis, D; Sonnenblick, EH | 1 |
| Keren, G; LeJemtel, TH; Mancini, D; Sonnenblick, EH | 1 |
2 review(s) available for dobutamine and 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2h)-pyridazinone
| Article | Year |
|---|---|
In search of the digitalis replacement.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Cyclic AMP; Digitalis Glycosides; Heart Failure; Humans; Myocardial Contraction; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1987 |
The role of novel inotropic agents in the treatment of heart failure.
Topics: Amrinone; Animals; Cardiotonic Agents; Dobutamine; Enoximone; Heart Failure; Hemodynamics; Humans; Imidazoles; Milrinone; Myocardial Contraction; Physical Exertion; Pyridazines; Pyridones; Time Factors | 1986 |
1 other study(ies) available for dobutamine and 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2h)-pyridazinone
| Article | Year |
|---|---|
CI-930, a new cardiotonic and vasodilating agent: hemodynamic comparison to dobutamine and long-term clinical effects.
Topics: Cardiotonic Agents; Dobutamine; Dose-Response Relationship, Drug; Female; Heart Failure; Hemodynamics; Humans; Middle Aged; Phosphodiesterase Inhibitors; Pyridazines; Time Factors | 1988 |